News | September 04, 2008

Digirad Developing New Cardiac SPECT Imaging System With Distortion Correction

September 5, 2008 - Digirad Corp. today announced the initial clinical trial of its new SPECT imaging system incorporating new proprietary technology to correct attenuation, an inherent issue in cardiac SPECT imaging.

The new system, Cardius X-ACT, will be exhibited at the 2008 Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) Sept. 10-14, 2008, at the John B. Hynes Convention Center in Boston.

Cardiac SPECT (single photon emission computed tomography) used for myocardial perfusion imaging is a noninvasive test to assess the heart’s structure and function. Small amounts of radioactive substances are injected into the patient’s vein, and gamma cameras produce images of the blood flow in the heart. These SPECT images are used to identify blockages in coronary arteries, determine whether a patient has had a heart attack, evaluate risk of a heart attack, and assess a patient’s condition after bypass surgery or angioplasty.

However, attenuation can cause misdiagnosis of the images, which is one of the most significant issues in cardiac SPECT. There are alternative solutions that attempt to address this problem, but Digirad said they involve tradeoffs, such as noisy images, truncated scans, lengthy procedures with risk of excess movement by patients, or higher levels of radiation dosage.

Research based using the company’s Cardius 3 triple-head SPECT camera, and feedback from initial clinical trials of the Cardius X-ACT at the University of California, Los Angeles (UCLA) is promising, compared to other SPECT systems at competitive price points, Digirad said. The company said the new device shows improvement in imaging clarity and accuracy, more rapid imaging, and a significant reduction in radiation dosage.

Two other clinical studies are planned for the Cardius X-ACT system, which is expected to be available for sale sometime in mid-2009 pending FDA approval.

For more information: www.digirad.com

Related Content

Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Overlay Init